EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis)

Luca Potestio, Cataldo Patruno, Alessandra Narcisi, Antonio Costanzo, Luciano Ibba, Luigi Gargiulo, Piergiorgio Malagoli, Michela Ortoncelli, Simone Ribero, Luca Mastorino, Francesco Leo, Silvia Mariel Ferrucci und 17 weitere

Archives of Dermatological Research · 2025

DOI: 10.1007/s00403-025-04278-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Luca Potestio und 28 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy. potestiol…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Sulfonamides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Napoli Federico II.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) prevalence in elderly patients is increasing. Clinically, elderly AD may present with atypical phenotypes, making the diagnosis difficult. Moreover, treatment challenges arise due to treatment-resistance, comorbidities, polypharmacy, and contraindications to existing therapies. Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) may offer a valuable alternative. However, their use in elderly populations remains unclear, as older patients are often excluded from clinical trials, and several concerns have been raised about their safety in this category of subjects. This study aimed to evaluate the efficacy and safety of JAK inhibitors in elderly patients with moderate-to-severe AD. A 52-week, multicenter, real-life study was performed enrolling patients aged ≥ 60 years affected by moderate-to-severe AD undergoing treatment with JAK inhibitors for at least 16 weeks across 16 dermatological centers in Italy. Disease severity was assessed at baseline, week (W) 4, 16, 24, and 52 using the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and Pruritus-Numerical Rating Scale (P-NRS). Adverse events (AEs) were recorded at each follow-up. A total of 72 patients met the inclusion criteria [abrocitinib: 13 (18.06%); baricitinib: 6 (8.33%); upadacitinib: 53 (73.61%)]. Of these, 72 (100.0%) achieved W16 follow-up with 33 (45.83%) and 26 (36.11%) subjects reaching W24 and W52, respectively. At baseline, mean EASI, DLQI and P-NRS were 21.22 ± 10.38, 18.21 ± 7.33, and 7.84 ± 1.94, respectively. A significant improvement in all scores was observed starting from W4 [EASI: 4.77 ± 5.07, DLQI: 4.01 ± 3.98, P-NRS: 1.66 ± 1.83 (p < 0.0001 for all)], continuing to improve up to W52 [EASI: 0.81 ± 1.27, DLQI: 0.31 ± 0.63, P-NRS: 0.42 ± 1.03; (p < 0.0001 for all)]. No treatment interruptions or modifications for ineffectiveness or AEs were registered. No statistically significant differences in terms of efficacy and safety were found among the treatment groups. JAK inhibitors demonstrated significant efficacy and an acceptable safety profile in elderly AD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsSulfonamidesHumansMaleFemaleAgedMiddle AgedPurinesAzetidinesSeverity of Illness IndexTreatment OutcomeItalyHeterocyclic Compounds, 3-RingPyrimidinesAged, 80 and overPyrazolesQuality of Life

Stichwörter der Autor:innen

AbrocitinibAtopic dermatitisBaricitinibElderly patientsJAK inhibitorsManagementUpadacitinib

Substanzen

Janus Kinase InhibitorsPurinesbaricitinibAzetidinesSulfonamidesupadacitinibabrocitinibHeterocyclic Compounds, 3-RingPyrimidinesPyrazoles

Autor:innen und Institutionen

  • Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy. potestioluca@gmail.com.
  • Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
  • Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Department of Dermatology, Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.
  • Departement of Clinical Medicine, Dermatologic Clinic, University of Turin, Turin, Italy.

Förderung

  • Università degli Studi di Napoli Federico II

Zitieren

APA

Potestio, L., Patruno, C., Narcisi, A., Costanzo, A., Ibba, L., Gargiulo, L., Malagoli, P., Ortoncelli, M., Ribero, S., Mastorino, L., Leo, F., Ferrucci, S. M., Angileri, L., Barei, F., Stingeni, L., Hansel, K., Sciarrone, C., Girolomoni, G., Maurelli, M., …, & Napolitano, M. (2025). Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis). Archives of Dermatological Research. https://doi.org/10.1007/s00403-025-04278-9

Vancouver

Potestio L, Patruno C, Narcisi A, Costanzo A, Ibba L, Gargiulo L, et al. Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis). Archives of Dermatological Research. 2025. doi:10.1007/s00403-025-04278-9

BibTeX
@article{Potestio2025,
  author = {Potestio, Luca and Patruno, Cataldo and Narcisi, Alessandra and Costanzo, Antonio and Ibba, Luciano and Gargiulo, Luigi and Malagoli, Piergiorgio and Ortoncelli, Michela and Ribero, Simone and Mastorino, Luca and Leo, Francesco and Ferrucci, Silvia Mariel and Angileri, Luisa and Barei, Francesca and Stingeni, Luca and Hansel, Katharina and Sciarrone, Claudio and Girolomoni, Giampiero and Maurelli, Martina and Foti, Caterina and Tirone, Benedetta and Balato, Anna and Esposito, Maria and Paolino, Giovanni and Mercuri, Santo Raffaele and Pezzolo, Elena and Savoia, Paola and Brescia, Claudio and Napolitano, Maddalena},
  title = {Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis)},
  journal = {Archives of Dermatological Research},
  year = {2025},
  doi = {10.1007/s00403-025-04278-9}
}
Kostenlos starten →